{Reference Type}: Journal Article
{Title}: Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study.
{Author}: Ewasiuk E;Emery J;Reid G;Saya S;
{Journal}: Pharmacogenomics
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 7
{Factor}: 2.638
{DOI}: 10.1080/14622416.2024.2382078
{Abstract}: Aim: To explore general practitioners' (GPs) views on implementing pharmacogenomic testing in Australian general practice. Methods: Semi-structured interviews were conducted with nine GPs in Australia, recruited from primary care networks. Interviews were analyzed using thematic analysis. Themes were mapped onto the Consolidated Framework for Implementation Research domains. Results: Barriers to implementation included lack of knowledge, education, standardized pharmacogenomic reports and national clinical guidelines and financial inaccessibility. Facilitators included positive exposure to pharmacogenomics, peer influences, interdisciplinary collaboration and proven clinical utility. Current uptake was minimal; however, GPs shared positive perceptions of clinical use. Conclusion: Recommendations for successful implementation include building and disseminating clinical evidence, developing national guidelines and standardized reports, incorporation into formal education and increasing financial accessibility.<BR>What is this article about? This article describes an original research study that examines the implementation of pharmacogenomic testing in Australian general practice. Pharmacogenomic testing applies personalized genomic information to medication prescribing, as genetic differences can affect how a person metabolizes certain medications. While there is excitement about the possibilities of using pharmacogenomics, the general uptake is slow. This study looked to understand the barriers and facilitators to implementation from the perspectives of general practitioners in Australia.What were the results? Through exploratory interviews with general practitioners, this study identified that barriers to implementation include a lack of knowledge, education, standardized reports and national clinical guidelines and financial inaccessibility. Facilitators include positive exposure to pharmacogenomic testing, peer influences, interdisciplinary collaboration and proven clinical utility. Current uptake was minimal; however, GPs shared positive perceptions of the potential of testing.What do the results of the study mean? Based on the results of this study, the following recommendations were generated for successful implementation: building and disseminating clinical evidence, developing national guidelines, incorporation into formal education, establishing accessible experts and improving financial accessibility.